Explore more publications!
Montserrat Tech Update
Got News to Share?

Montserrat Tech Update: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Montserrat Tech Update.

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Press releases published on May 1, 2026

SalesCloser Secures U.S. Patent for AI-Powered Conversational Workflow Technology
May. 1, 2026

SalesCloser Secures U.S. Patent for AI-Powered Conversational Workflow Technology

Indeterminate GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Carbonara Announces Run for U.S. Congress in Florida's Redrawn 22nd District
May. 1, 2026

Carbonara Announces Run for U.S. Congress in Florida's Redrawn 22nd District

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
May. 1, 2026

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

Indeterminate GlobeNewswire
Fort Lauderdale Commissioner John Herbst Endorses Michael Carbonara for Congress in FL-22
May. 1, 2026

Fort Lauderdale Commissioner John Herbst Endorses Michael Carbonara for Congress in FL-22

Indeterminate GlobeNewswire
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
May. 1, 2026

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Indeterminate GlobeNewswire
Trident Announces Receipt of Nasdaq Determination Letter and Intent to Request Hearing
May. 1, 2026

Trident Announces Receipt of Nasdaq Determination Letter and Intent to Request Hearing

Indeterminate GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
May. 1, 2026

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

Indeterminate GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
May. 1, 2026

Spyre Therapeutics Announces Grants of Inducement Awards

Indeterminate GlobeNewswire
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
May. 1, 2026

InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

Indeterminate GlobeNewswire
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
May. 1, 2026

InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System

Indeterminate GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May. 1, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May. 1, 2026

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions